Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

Core Insights - Agenus Inc. announced new data from its botensilimab (BOT) immunotherapy program will be presented at the AACR-IO Conference, focusing on systemic and tumor inflammation biomarkers in immunologically cold tumors [1] Group 1: Presentation Details - The poster presentation titled "Systemic and tumor-microenvironment inflammation shape outcomes in patients with immunologically cold, treatment-refractory tumors treated with Fc-enhanced anti–CTLA-4 botensilimab" will evaluate the association of systemic inflammatory markers and tumor microenvironment immune activity with clinical outcomes [1] - The presentation will take place on February 19, 2026, from 12:15 PM to 3:15 PM PT at the JW Marriott, Platinum Ballroom [1] Group 2: About Botensilimab and Balstilimab - Botensilimab is designed to enhance both innate and adaptive anti-tumor immune responses, particularly in "cold" tumors that typically respond poorly to standard therapies [1] - Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in clinical trials, showing clinical responses across nine metastatic, late-line cancers [1] - Balstilimab is a fully human monoclonal antibody that blocks PD-1 from interacting with its ligands, having been evaluated in over 900 patients with a favorable tolerability profile [1] Group 3: Company Overview - Agenus is a leader in immuno-oncology with a comprehensive pipeline of immunological agents, founded in 1994, aiming to expand patient populations benefiting from cancer immunotherapy [1] - The company has robust development capabilities, including commercial and clinical cGMP manufacturing facilities, research, and global clinical operations [1]